CD3 Inhibitor

Gamgertamig is a humanized IgG4 bispecific antibody targeting TNFRSF17 & CD3E.

Anti-CD3 Antibody (UCHT-1) is an antibody targeting CD3. Anti-CD3 Antibody (UCHT-1) activates the phospholipase C and phosphatidylinositol 3-kinase (PI3K) signaling pathways, elevates intracellular calcium levels, regulates the T3 epitope, and triggers T lymphocyte proliferation. Anti-CD3 Antibody (UCHT-1) also inhibits lymphocyte proliferation, abolishes IL-2 production, and blocks the expression of IL-2 receptors. Anti-CD3 Antibody (UCHT-1) is applicable to research related to graft-versus-host disease, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia.

Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research.

Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv).

Ebribafusp alfa (ADX-097) comprising a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of factor H (fH1-5). Ebribafusp alfa binds C3d and related fragments, catalyzes AP convertase dissociation, acts as a factor I co-factor for C3b cleavage, and delivers fH1-5 moieties to C3d-deposited tissues for local complement inhibition without systemic blockade. Ebribafusp alfa reduces glomerular C3 deposition, proteinuria, urine albumin-creatinine ratios, and urine soluble C5b-9 levels, preserves podocyte foot-process architecture, inhibits skin complement activation, and localizes to UVB-damaged primate skin. Ebribafusp alfa can be used for the research of membranous nephropathy, bullous pemphigoid, discoid lupus erythematosus, C3 glomerulopathy, IgA nephropathy, and lupus nephritis.

Lck-IN-5 (example C10) is a potent and selective lymphocyte-specific protein tyrosine kinase (LCK) inhibitor. Lck-IN-5 selectively disrupts the interaction between the SH3 domain of LCK and the RK motif of CD3ε, thereby impairing LCK recruitment to the TCR. Lck-IN-5 modulates the activity of CD3ε-containing CAR and TRuC T cells, attenuating cytokine production and promoting a central-memory-like phenotype associated with enhanced persistence. Lck-IN-5 can be used for autoimmune diseases and graft-versus-host disease research.

Mipletamig (APVO-436) is a bispecific CD123 x CD3 monoclonal antibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML).

Podentamig (HPN 217) is a trispecific construct with three binding domains, including an anti-CD3 domain for T cell activation, an anti-BCMA domain for binding to plasma cells, and an anti-albumin domain for half-life extension. Podentamig is applicable to research related to relapsed/refractory multiple myeloma.

Torutamig is a monoclonal antibody targeting TNFRSF17/BCMA/CD269&CD3E.

Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing.

Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells.

HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on T cells, and to serum albumin. HPN536 specifically redirects T cells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation.

Varzutamig is a bispecific antibody targeting CD3E/ALB/EGFR.

Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research.

Lumivatamig is an H-γ1_L-κ-scFvhl dimer-type bispecific antibody targeting CLDN18.2 & CD3E.

Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers.

PF-07260437 is a bispecific monoclonal antibody targeting B7-H4 and CD3, with K_d values of 63.5 nM and 66.75 nM against human and cynomolgus monkey CD3, respectively. PF-07260437 simultaneously binds B7-H4 on tumor cells and the CD3ε subunit in the T cell receptor complex, forming a tumor cell-bispecific antibody-T cell trimer. This process establishes an immune synapse and initiates non-MHC-dependent T cell activation, proliferation, and release of cytotoxic molecules such as granzyme B to kill tumor cells. PF-07260437 can be used in research related to advanced or metastatic breast cancer, ovarian cancer, and endometrial cancer.

Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).

MS133 is a human bispecific antibody (bsAb) targeting CD133/PROM1 & CD3E. MS133 can be used in colon cancer research.